Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Nijiati Aierken"'
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Previous studies have shown a relationship between SPECC1 and the prognosis of breast cancer, indicating a potential function for SPECC1 in the initiation and progression of cancer. However, the role played by SPECC1 in other tumors is not y
Externí odkaz:
https://doaj.org/article/bf374a35b73245968e58e25012f30149
Autor:
Runyi Ye, NiJiati AiErken, Xiaying Kuang, Huijuan Zeng, Nan Shao, Ying Lin, Pian Liu, Shenming Wang
Publikováno v:
Oncogenesis, Vol 10, Iss 9, Pp 1-10 (2021)
Abstract Tamoxifen resistance remains a clinical problem in estrogen receptor (ER)-positive breast cancer. SUMOylation of ERα enhances ERα-induced transcription activity. Tripartite motif-containing (TRIM) proteins are a new class of SUMO E3 ligase
Externí odkaz:
https://doaj.org/article/c5a8fb33df9241d5a1eb8148024d0c10
Autor:
Xianghong He, Miaochun Zhong, Qian Zhang, Nijiati Aierken, Lingfei Cui, Zhaomin Xing, Kefeng Lei
Publikováno v:
Cancer Treatment and Research Communications, Vol 31, Iss , Pp 100525- (2022)
Introduction: Breast cancer (BC) and thyroid dysfunction are common in females, yet the relationship between thyroid hormone and BC is unclear. To search for the connection between thyrotropin and BC, we contradistinguished BC patients with or withou
Externí odkaz:
https://doaj.org/article/4c55a55402ce45a58e5baab1914cfad2
Autor:
Yawei Shi, Yang Zhao, Yunjian Zhang, NiJiati AiErken, Nan Shao, Runyi Ye, Ying Lin, Shenming Wang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 37, Iss 1, Pp 1-10 (2018)
Abstract Background Although tamoxifen is a highly effective drug for treating estrogen receptor–positive (ER+) breast cancer, nearly all patients with metastasis with initially responsive tumors eventually relapse, and die from acquired drug resis
Externí odkaz:
https://doaj.org/article/6eac0d9e7bb743d9bd64d41f8b9fdb9d
Autor:
Nijiati, Aierken, Cui, Lingfei, Wang, Xidi, Xing, Zhaomin, Zhang, Mingxia, Yuan, Zhuolin, Xie, Wenyu, Lei, Kefeng
Publikováno v:
In Heliyon 15 January 2024 10(1)
Autor:
NiJiati AiErken, Pian Liu, Ying Lin, Huijuan Zeng, Nan Shao, Shenming Wang, Runyi Ye, Xiaying Kuang
Publikováno v:
Oncogenesis, Vol 10, Iss 9, Pp 1-10 (2021)
Tamoxifen resistance remains a clinical problem in estrogen receptor (ER)-positive breast cancer. SUMOylation of ERα enhances ERα-induced transcription activity. Tripartite motif-containing (TRIM) proteins are a new class of SUMO E3 ligases, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5276728df557e8c4106467ec7fb806b0
https://doaj.org/article/c5a8fb33df9241d5a1eb8148024d0c10
https://doaj.org/article/c5a8fb33df9241d5a1eb8148024d0c10
Autor:
Yuhong Liu, Yixiang Gan, NiJiati AiErken, Wei Chen, Shiwei Zhang, Jie Ouyang, Leli Zeng, Di Tang
Publikováno v:
Journal of oncology. 2022
Estrogen receptor-positive (ER+) breast cancer (BC) is a common subtype of BC with a relatively good prognosis. However, recurrence and death from ER+ BC occur because of tumor heterogeneity. This study aimed to explore tumor heterogeneity using next
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65482606adaaf3825ea4b609f6aeba7b
https://pubmed.ncbi.nlm.nih.gov/36046364
https://pubmed.ncbi.nlm.nih.gov/36046364
Autor:
NiJiati AiErken, Ying Lin, Yawei Shi, Shenming Wang, Runyi Ye, Nan Shao, Yunjian Zhang, Yang Zhao
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 37, Iss 1, Pp 1-10 (2018)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
Background Although tamoxifen is a highly effective drug for treating estrogen receptor–positive (ER+) breast cancer, nearly all patients with metastasis with initially responsive tumors eventually relapse, and die from acquired drug resistance. Un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fa2d53aa38bdb4df80c664d4e3d5b0f
http://link.springer.com/article/10.1186/s13046-018-0928-7
http://link.springer.com/article/10.1186/s13046-018-0928-7
Autor:
Shenming Wang, Nan Shao, Yawei Shi, Runyi Ye, Yang Zhao, Yunjian Zhang, Ying Lin, NiJiati AiErken
Publikováno v:
Life Sciences. 208:161-166
Aims Breast cancer is the major diagnosed cancer and the leading reason of cancer related death among women, and the tumor size is one of the risk factors. Therefore, it is significant to reveal the principle of breaking the subtle homeostasis of cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb8f546774521a3d62a05e6351ae39dc
https://doi.org/10.1016/j.lfs.2018.07.034
https://doi.org/10.1016/j.lfs.2018.07.034